The FDA approved obinutuzumab (Gazyva) or use in combination with chlorambucil to treat patients with previously untreated CLL, ibrutinib (Imbruvica) received FDA approval for the treatment of mantle cell lymphoma, and other FDA actions.
High rates of freedom from disease, overall survival for standard-dose, with lower-dose EPOCH-R treatment.
Drug designed to inhibit enzyme that cancer cells need to spread is granted "breakthrough therapy" status by FDA.
Oncologists are adding new agents to their arsenal against mantle cell lymphoma.
Vaccines and monoclonal antibodies are promising new treatments for patients with follicular lymphoma.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|